Expert review of respiratory medicine最新文献_第2页

The prognostic role of lung ultrasound in hospitalised patients with COVID-19. Correlation with chest CT findings and clinical markers of severity.

Expert review of respiratory medicine Pub Date : 2025-02-27 DOI: 10.1080/17476348.2025.2471776

Ioannis Tomos, Elvira Markela Antonogiannaki, Konstantina Dimakopoulou, Thomas Raptakis, Vasiliki Apollonatou, Maria Kallieri, Stylianos Argentos, Stefanos Lampadakis, Myrto Blizou, Antonis Krouskos, Anna Karakatsani, Effrosyni Manali, Stylianos Loukides, Spyros Papiris

{"title":"The prognostic role of lung ultrasound in hospitalised patients with COVID-19. Correlation with chest CT findings and clinical markers of severity.","authors":"Ioannis Tomos, Elvira Markela Antonogiannaki, Konstantina Dimakopoulou, Thomas Raptakis, Vasiliki Apollonatou, Maria Kallieri, Stylianos Argentos, Stefanos Lampadakis, Myrto Blizou, Antonis Krouskos, Anna Karakatsani, Effrosyni Manali, Stylianos Loukides, Spyros Papiris","doi":"10.1080/17476348.2025.2471776","DOIUrl":"10.1080/17476348.2025.2471776","url":null,"abstract":"Background: The use of lung ultrasound (LUS) has recently become vital in the diagnosis and prognosis of various respiratory diseases. Its role in COVID-19 requires further investigation.Research design and methods: Twenty-five consecutive, non-ICU hospitalized COVID-19 patients were included. LUS was performed on admission and sequentially every 3 days at 8 points in the chest. Based on the LUS findings a score was designed. Logarithmic regression models and ROC curve analysis were applied.Results: A statistically significant positive correlation was found between LUS score at admission and the severity of SARS-COV-2 infection. Higher LUS score was significantly associated with lower PaO2/FiO2 ratio, use of HFNC, longer hospitalization and greater extent of chest CT infiltrates. A significant association between LUS score and risk of death or intubation or HFNC was found. For one point of increase in the score, risk of death or intubation or HFNC increased 1.93-fold (95% CI 1.02 to 3.65). The predictive role of the score was very satisfactory (area under the ROC curve = 0.87).Conclusions: Lung ultrasound findings were significantly positively associated with clinical and radiological markers of severity of SARS-CoV-2 pneumonia. It therefore constitutes a promising and reliable technique for assessing pneumonia, comparable to chest CT.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic underpinning of idiopathic pulmonary fibrosis: the role of mucin.

Expert review of respiratory medicine Pub Date : 2025-02-25 DOI: 10.1080/17476348.2025.2464035

Seyedeh Zahra Fotook Kiaei, David A Schwartz

{"title":"Genetic underpinning of idiopathic pulmonary fibrosis: the role of mucin.","authors":"Seyedeh Zahra Fotook Kiaei, David A Schwartz","doi":"10.1080/17476348.2025.2464035","DOIUrl":"10.1080/17476348.2025.2464035","url":null,"abstract":"Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive scarring and reduced survival. The development of IPF is influenced by rare and common genetic variants, cigarette smoking, aging, and environmental exposures. Among the two dozen genetic contributors, the MUC5B promoter variant (rs35705950) is the dominant risk factor, increasing the risk of both familial and sporadic IPF and accounting for nearly 50% of the genetic predisposition to the disease.Areas covered: This review provides an expert perspective on the genetic underpinnings of IPF rather than a systematic analysis, emphasizing key insights into its genetic basis. The articles referenced in this review were identified through targeted searches in PubMed, Scopus, and Web of Science for studies published between 2000 and 2023, prioritizing influential research on the genetic factors contributing to IPF. Search terms included 'idiopathic pulmonary fibrosis,' 'genetics,' 'MUC5B,' 'telomere dysfunction,' and 'surfactant proteins.' The selection of studies was guided by the authors' expertise, focusing on the most relevant publications.Expert opinion: The identification of genetic variants not only highlights the complexity of IPF but also offers potential for earlier diagnosis and personalized treatment strategies targeting specific genetic pathways, ultimately aiming to improve patient outcomes.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emerging role of anticoagulants targeting Factor XI in thromboembolism management.

Expert review of respiratory medicine Pub Date : 2025-02-20 DOI: 10.1080/17476348.2025.2467463

Laurent Bertoletti, Jean Escal, Lutfi Ozturk, Margaux Geier, Géraldine Poenou

引用次数: 0

Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer.

Expert review of respiratory medicine Pub Date : 2025-02-20 DOI: 10.1080/17476348.2025.2467338

Nazmul Hasan, Misako Nagasaka

引用次数: 0

The prognostic value of NT-proBNP in 28-day mortality and post-discharge survival in pneumonia: a retrospective cohort study from Taiwan.

Expert review of respiratory medicine Pub Date : 2025-02-18 DOI: 10.1080/17476348.2025.2467339

Van-Dong Nguyen, Hsien-Chun Lin, Wen-Chen Lee, Ke-Shiuan Ju, Jing-En Dai, Pei-Ni Hsieh, Chun-You Chen, Chih-Hsin Lee

{"title":"The prognostic value of NT-proBNP in 28-day mortality and post-discharge survival in pneumonia: a retrospective cohort study from Taiwan.","authors":"Van-Dong Nguyen, Hsien-Chun Lin, Wen-Chen Lee, Ke-Shiuan Ju, Jing-En Dai, Pei-Ni Hsieh, Chun-You Chen, Chih-Hsin Lee","doi":"10.1080/17476348.2025.2467339","DOIUrl":"10.1080/17476348.2025.2467339","url":null,"abstract":"Background: NT-proBNP, traditionally used to assess heart failure, is increasingly recognized for its prognostic value in other diseases. This study evaluates its value in pneumonia.Research design and methods: We conducted a retrospective cohort study of adult patients hospitalized for pneumonia at Wan Fang Hospital (2017-2021) to investigate whether elevated NT-proBNP levels predicted poorer outcomes. Logistic regression identified risk factors for 28-day mortality, while the Cox regression model identified predictors of post-discharge survival.Results: Among 2,805 patients (79.6 ± 13.4 years, female 45%), the 28-day mortality rate was 18.2%, and the median post-discharge follow-up time was 359 days. Moderately (increased but < 10000 pg/mL) and severely (>10000 pg/mL) elevated NT-proBNP levels had higher 28-day mortality compared to normal NT-proBNP; adjusted odds ratios: 2.24 (1.34-3.75, p = 0.002) and 3.57 (2.03-6.27, p < 0.001). Moderately and severely elevated NT-proBNP levels related to shorter survival time than normal NT-proBNP levels; adjusted hazard ratios 1.60 (1.28-2.00, p < 0.001) and 2.03 (1.56-2.63, p < 0.001). All ratios were adjusted with comorbidities, sex, age, and clinical and laboratory tests.Conclusions: Elevated NT-proBNP levels predict higher 28-day mortality and shorter survival time in patients with pneumonia across most subpopulations. This marker holds potential as a prognostic biomarker for pneumonia, especially in high-risk patients.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathophysiology of small airways in idiopathic pulmonary fibrosis (IPF): the silent zone.

Expert review of respiratory medicine Pub Date : 2025-02-17 DOI: 10.1080/17476348.2025.2467341

Wenying Lu, Affan Mahmood Shahzad, Athul Antony Simon, Greg Haug, Maddison Waters, Sukhwinder Singh Sohal

{"title":"Pathophysiology of small airways in idiopathic pulmonary fibrosis (IPF): the silent zone.","authors":"Wenying Lu, Affan Mahmood Shahzad, Athul Antony Simon, Greg Haug, Maddison Waters, Sukhwinder Singh Sohal","doi":"10.1080/17476348.2025.2467341","DOIUrl":"10.1080/17476348.2025.2467341","url":null,"abstract":"Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by distorted alveolar structure and reduced lung compliance, and impaired ventilation-perfusion. Small airway disease (SAD) is often termed a 'quietzone' due to its asymptomatic nature. Around 30-40% of IPF patients exhibit SAD, which is associated with worse prognosis, higher fibrosis and emphysema scores, and elevated mortality risk. We used PubMed and Google Scholar for literature search.Areas covered: This review explores the pathophysiology of small airways in IPF, focusing on 1. Risk factors, including age, gender, smoking and occupational dust exposure, and ozone. 2. Diagnostic challenges: SAD is difficult to detect through traditional spirometry or high-resolution computed tomography imaging due to resolution limitations. 3. Early physiological changes of small airways include airway wall thickening, lumen distortion, and reduced terminal bronchioles, preceding microscopic fibrosis, occurs in the early process of IPF. 4. Pathological mechanisms: The review examines the underlying mechanisms driving small airway disease in IPF.Expert opinion: A comprehensive approach is essential to improve the understanding and management of SAD in IPF. Priorities include identifying therapeutic targets, advanced imaging and functional assessments. Forced oscillation technique should be introduced for early detection for small airway abnormalities in IPF.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for preventing and reducing the impact of acute respiratory failure from pneumonia.

Expert review of respiratory medicine Pub Date : 2025-02-15 DOI: 10.1080/17476348.2025.2464880

Joon Yong Moon, Mohamad El Labban, Ognjen Gajic, Yewande Odeyemi

{"title":"Strategies for preventing and reducing the impact of acute respiratory failure from pneumonia.","authors":"Joon Yong Moon, Mohamad El Labban, Ognjen Gajic, Yewande Odeyemi","doi":"10.1080/17476348.2025.2464880","DOIUrl":"10.1080/17476348.2025.2464880","url":null,"abstract":"Introduction: Pneumonia remains a leading cause of morbidity and mortality, particularly in critically ill patients with acute respiratory failure (ARF). This review discusses prevention strategies for pneumonia-induced ARF, categorized into primary, secondary, and tertiary prevention.Areas covered: A literature search was conducted through PubMed covering the years 2000-2024, using the keywords 'acute respiratory failure,' pneumonia prevention,\" 'risk stratification,' and 'preventive strategies.' Primary prevention focuses on reducing pneumonia risk through vaccination, smoking cessation, and comorbidity management. Secondary prevention involves early detection, risk assessment using clinical tools like the Pneumonia Severity Index (PSI) biomarkers, such as procalcitonin and C-reactive protein, appropriate antibiotic use, and emerging machine learning tools for real-time stratification. Tertiary prevention focuses on optimizing care with noninvasive respiratory support, lung-protective ventilation strategies, and ventilator bundles for intubated patients. Emerging therapies, including targeted use of corticosteroids and other immunomodulatory agents, are also discussed as promising adjuncts to current standards of care.Expert opinion: While these prevention strategies show potential, continued research is necessary to refine these interventions, explore newer therapies and evaluate long-term outcomes. Implementation of these strategies aims to reduce the impact of pneumonia-induced ARF on healthcare systems and improve patient survival and quality of care.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-17"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thoracoabdominal normothermic regional perfusion in organ donation: a comprehensive review of current evidence and best practices.

Expert review of respiratory medicine Pub Date : 2025-02-12 DOI: 10.1080/17476348.2025.2464877

Kentaro Nakata, Matthew G Hartwig

引用次数: 0

Inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review and meta-analysis on mortality protection - making a long story short.

Expert review of respiratory medicine Pub Date : 2025-02-12 DOI: 10.1080/17476348.2025.2465853

Paola Rogliani, Gan Marco Manzetti, Shima Gholamalishahi, Mona Bafadhel, Luigino Calzetta

{"title":"Inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review and meta-analysis on mortality protection - making a long story short.","authors":"Paola Rogliani, Gan Marco Manzetti, Shima Gholamalishahi, Mona Bafadhel, Luigino Calzetta","doi":"10.1080/17476348.2025.2465853","DOIUrl":"10.1080/17476348.2025.2465853","url":null,"abstract":"Introduction: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality worldwide, primarily due to persistent airflow limitation from tobacco and biomass smoke exposure. While inhaled corticosteroids (ICS) combined with long-acting bronchodilators, namely long-acting β2-adrenoreceptor agonists (LABA) and long-acting muscarinic antagonists (LAMA), are recommended for symptom control and exacerbation reduction, their effect on mortality remains uncertain. Recent randomized controlled trials (RCTs) suggest potential mortality benefits with triple ICS/LABA/LAMA therapy, though findings are not definitive.Methods: We conducted a systematic review and network meta-analysis (NMA) to evaluate the impact of ICS-containing therapies on all-cause mortality in COPD. Searches were performed across ClinicalTrials.gov, Cochrane Library, EMBASE, MEDLINE, and SCOPUS, focusing on RCTs measuring mortality as an efficacy outcome.Results: A total of 42,784 COPD patients from five high-quality studies were included. Pairwise meta-analysis showed a significant reduction in all-cause mortality with ICS-containing therapies (RR 0.80, 95% CI 0.68-0.95), particularly with ICS/LABA and ICS/LABA/LAMA combinations. The NMA ranked ICS/LABA/LAMA as the most effective treatment (SUCRA 0.89).Conclusions: This study provides compelling evidence that ICS-containing therapies, particularly triple therapy, significantly reduce all-cause mortality in COPD patients. Future research should identify patient subgroups most likely to benefit while minimizing adverse effects.Registration: PROSPERO registration ID: CRD42024607568.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burden and regional disparities of chronic obstructive pulmonary disease in India: Insights from the global burden of disease data and projections for future incidence.

Expert review of respiratory medicine Pub Date : 2025-02-12 DOI: 10.1080/17476348.2025.2464882

Vijay Kumar, Mahendra Singh, Mahalaqua Nazli Khatib, Ashok Kumar Balaraman, Rangaswamy Roopashree, Mandeep Kaur, Manish Srivastava, Amit Barwal, G V Siva Prasad, Pranchal Rajput, Rukshar Syed, Gajendra Sharma, Sunil Kumar, Ganesh Bushi, Nagavalli Chilakam, Sakshi Pandey, Manvinder Brar, Rachana Mehta, Sanjit Sah, Muhammed Shabil, Abhay M Gaidhane

{"title":"Burden and regional disparities of chronic obstructive pulmonary disease in India: Insights from the global burden of disease data and projections for future incidence.","authors":"Vijay Kumar, Mahendra Singh, Mahalaqua Nazli Khatib, Ashok Kumar Balaraman, Rangaswamy Roopashree, Mandeep Kaur, Manish Srivastava, Amit Barwal, G V Siva Prasad, Pranchal Rajput, Rukshar Syed, Gajendra Sharma, Sunil Kumar, Ganesh Bushi, Nagavalli Chilakam, Sakshi Pandey, Manvinder Brar, Rachana Mehta, Sanjit Sah, Muhammed Shabil, Abhay M Gaidhane","doi":"10.1080/17476348.2025.2464882","DOIUrl":"10.1080/17476348.2025.2464882","url":null,"abstract":"Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally, particularly in low- and middle-income countries like India. This study aims to analyze regional trends and project future burden of COPD in India using data from the Global Burden of Disease (GBD) 1990-2021.Methods: This analysis utilized data from the GBD study to assess age-standardized prevalence (ASPR), incidence (ASIR), disability-adjusted life years (DALYs) (ASDR), and mortality rates (ASMR) for COPD across Indian states. Joinpoint regression was used to analyze temporal trends, while ARIMA models predicted future incidence rates.Results: In 2021, the highest ASIR was observed in Rajasthan at 306.28, and the highest ASMR was observed in Uttarakhand at 227.19. Projections suggest that the ASIR for COPD in India will decrease from 265.16 in 2022 to 258.19 by 2031. The heatmap analysis identified states like Uttarakhand and Rajasthan as having the highest DALYs attributable to COPD risk factors, including air pollution and tobacco use.Conclusion: COPD remains a public health challenge in India, with regional variability. Targeted interventions addressing air pollution, smoking cessation, and improved healthcare access are essential to mitigate the disease's future burden, particularly in high-risk regions.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0